Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 15;11:3253–3264. doi: 10.2147/CMAR.S193793

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Wang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

The interaction between CDKN3 and RAD51 in ESCA. (A–B) CDKN3-regulated cisplatin-induced γH2AX foci (A) and quantitative results (B) in ESCA. Scale bar=5 μm. (C) CDKN3 knockdown regulated cisplatin chemoresistance-related proteins. (D) Correlation between CDKN3 and RAD51 mRNA expression in TCGA ESCA dataset. (E–F) Interaction between endogenous CDKN3 and RAD51 in EC109R (E) and OE19R (F) cell lines by Co‑IP. ***P<0.001.

Abbreviations: EC109R, cisplatin-resistant EC109 cell line; OE19R, cisplatin-resistant OE19 cell line; NC, negative control; shCDKN3, cells transfected with shCDKN3 plasmid; RSEM, RNA-Seq by Expectation-Maximization.